Logo do repositório
 
Publicação

Unveiling new secrets in Parkinson's disease

2023-03-28Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorChegão, Ana
dc.contributor.authorVicente Miranda, Hugo
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.institutioniNOVA4Health - pólo NMS
dc.contributor.pblElsevier
dc.date.accessioned2023-02-13T22:19:25Z
dc.date.available2023-02-13T22:19:25Z
dc.date.issued2023-03-28
dc.descriptionFunding Information: This study was supported by iNOVA4Health UID/Multi/04462/2013 – UIDB/04462/2020 and UIDP/04462/2020 , a program financially supported by Fundação para a Ciência e a Tecnologia (FCT) / Ministério da Ciência, Tecnologia e Ensino Superior, through national funds; and by Sociedade Portuguesa de Diabetologia . AC was supported by PD/BD/136863/2018 , FCT.
dc.description.abstractWe are witnessing a considerable increase in the incidence of Parkinson's disease (PD), which may be due to the general ageing of the population. While there is a plethora of therapeutic strategies for this disease, they still fail to arrest disease progression as they do not target and prevent the neurodegenerative process. The identification of disease-causing mutations allowed researchers to better dissect the underlying causes of this disease, highlighting, for example, the pathogenic role of alpha-synuclein. However, most PD cases are sporadic, which is making it hard to unveil the major causative mechanisms of this disease. In the recent years, epidemiological evidence suggest that type-2 diabetes mellitus (T2DM) individuals have higher risk and worst outcomes of PD, allowing to raise the hypothesis that some dysregulated processes in T2DM may contribute or even trigger the neurodegenerative process in PD. One major consequence of T2DM is the unprogrammed reaction between sugars, increased in T2DM, and proteins, a reaction named glycation. Pre-clinical reports show that alpha-synuclein is a target of glycation, and glycation potentiates its pathogenicity which contributes for the neurodegenerative process. Moreover, it triggers, anticipates, or aggravates several PD-like motor and non-motor complications. A given profile of proteins are differently glycated in diseased conditions, altering the brain proteome and leading to brain dysfunction and neurodegeneration. Herein we coin the term Glycatome as the profile of glycated proteins. In this review we report on the mechanisms underlying the association between T2DM and PD, with particular focus on the impact of protein glycation.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent3454638
dc.identifier.doi10.1016/j.bbr.2023.114309
dc.identifier.issn0166-4328
dc.identifier.otherPURE: 53067435
dc.identifier.otherPURE UUID: dd150657-2a10-4045-912f-4221b136a5f0
dc.identifier.otherScopus: 85147354129
dc.identifier.otherPubMed: 36706808
dc.identifier.urihttp://hdl.handle.net/10362/149147
dc.identifier.urlhttps://www.scopus.com/pages/publications/85147354129
dc.language.isoeng
dc.peerreviewedyes
dc.subjectAlpha-synuclein
dc.subjectGlycation
dc.subjectGlycatome
dc.subjectParkinson's disease
dc.subjectType-2 diabetes
dc.subjectBehavioral Neuroscience
dc.subjectSDG 3 - Good Health and Well-being
dc.titleUnveiling new secrets in Parkinson's diseaseen
dc.title.subtitleThe glycatomeen
dc.typejournal article
degois.publication.titleBehavioural Brain Research
degois.publication.volume442
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
1_s2.0_S016643282300027X_main.pdf
Tamanho:
3.29 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS: iNOVA4Health - Artigos em revista internacional com arbitragem científica